Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck
| Autor: | Regina Riedl, Edgar Selzer, Sabine Reinisch, Herbert Kainz, Richard Greil, Karin S. Kapp, A. K. Kasparek, W. Anderhuber, Christoph Tinchon, Andrea Berghold, Martin Burian, Gabriela Kornek, Barbara Bachtiary, Michael Kopp, Alexander de Vries, Wolfgang Elsäßer, Felix Keil |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Cetuximab Docetaxel Antibodies Monoclonal Humanized Loading dose Disease-Free Survival Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans Aged Squamous Cell Carcinoma of Head and Neck business.industry Head and neck cancer Antibodies Monoclonal Induction chemotherapy Induction Chemotherapy Middle Aged medicine.disease Radiation therapy Head and Neck Neoplasms Fluorouracil Carcinoma Squamous Cell Female Taxoids Cisplatin business medicine.drug |
| Zdroj: | European Journal of Cancer. 49:352-359 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/j.ejca.2012.08.004 |
| Popis: | Purpose To determine the efficacy and feasibility of induction chemotherapy (ICT) with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy and cetuximab (C) in patients with locally advanced head and neck cancer. Patients and methods Forty-nine previously untreated patients with local advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) received three courses of ICT consisting of docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1 and infusional 5-fluorouracil 750 mg/m2/day on days 1–5 followed by radiotherapy plus C at 250 mg/m2/week (after an initial loading dose of 400 mg/m2). Results After completion of ICT 44 of 49 patients received radiotherapy plus C. Three months after therapy completion tumour response was observed in 33 patients and after two years, 25 patients were in complete remission (CR). The most common grade 4 toxicity during the whole treatment period was dermatitis (30%), followed by mucositis (27%) and neutropenia (17%) without fever. One toxic related death was observed during ICT. Two-year progression-free survival (PFS) rate was 59% and two-year overall survival (OS) rate was 63%, respectively. Conclusion Concurrent radiotherapy plus C after three courses of ICT was feasible and was associated with promising CR, PFS and OS rates. Further optimisation of dose and sequence is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect